Prevalence of systemic lupus erythematosus in Colombia: data from the national health registry 2012–2016

Fernández-Ávila, Daniel G.; Bernal-Macías, Santiago; Rincón-Riaño, Diana N.; Dávila, Juan Martín Gutiérrez; Rosselli, Diego

doi:10.1177/0961203319864168

Cited by 44 publications

(23 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[ 1 ] Systemic lupus erythematosus (SLE) is one among the most common autoimmune disorders affecting females of child-bearing age. [ 2 ] As stated in other studies, research concerning SLE in pregnant women have often been limited to a particular ethnic group, or most of the time to a specific region. [ 3 , 4 ] Therefore, to generalize this issue, Bundhun et al clearly demonstrated the impact of SLE on maternal and fetal outcomes through a meta-analysis including various studies from different parts of the globe and included studies which were published between the years 2001 and 2016.…”

Section: Introductionmentioning

confidence: 99%

Maternal and fetal complications associated with systemic lupus erythematosus

Hua

2020

Medicine

View full text Add to dashboard Cite

Background: Recent guidelines provide better treatment and management of pregnancy in women with systemic lupus erythematosus (SLE). In this analysis, we aimed to systematically assess the maternal and fetal complications associated with SLE using the most recent studies (2017–2019) to obtain an updated result of the present situation. Methods: http://www.clinicaltrials.gov , MEDLINE, Cochrane Central, Web of Science, EMBASE, and Google Scholar were searched for English based studies comparing maternal and fetal complications in pregnant women with versus without SLE. Maternal and fetal complications were the endpoints in this analysis. The RevMan software 5.3 (latest version) was the most suitable analytical software for this analysis. Data were represented by risk ratio (RR) with 95% confidence interval (CI). Results: A total number of eight million eight hundred and twelve thousand two hundred seventy-two (8,812,272) participants were included in this analysis, consisting of 9696 SLE-associated pregnancy. Based on an analysis of recently published studies (2017–2019), pre-eclampsia/eclampsia was significantly higher in pregnant women with SLE (RR: 3.38, 95% CI: 3.15–3.62; P = .00001). SLE was also associated with an increased risk of stillbirth (RR: 16.49, 95% CI: 2.95–92.13; P = .001) and fetal loss (RR: 7.55, 95% CI: 4.75–11.99; P = .00001). Abortion (RR: 4.70, 95% CI: 3.02–7.29; P = .00001) and the risk for cesarean section due to complications (RR: 1.38, 95% CI: 1.11–1.70; P = .003) were also significantly higher in pregnant women with SLE. In addition, fetal complications including preterm birth (RR: 2.33, 95% CI: 1.78–3.05; P = .00001), infants who were small for gestational age (RR: 2.50, 95% CI: 1.41–4.45; P = .002) and infants with low birth weight (RR: 4.78, 95% CI: 3.65–6.26; P = .00001) were also significantly higher in newborns from mothers with SLE. Moreover, the risk of newborns who were admitted to the neonatal intensive care unit (RR: 2.79, 95% CI: 2.31–3.37; P = .00001), newborns with an APGAR score <7 within 1 minute (RR: 2.47, 95% CI: 1.68–3.62; P = .00001) and 5 minutes (RR: 3.63, 95% CI: 2.04–6.45; P = .0001) respectively, were significantly highly associated with SLE. Conclusions: Based on the most recent studies, we could conclude that maternal and fetal complications were significantly higher in SLE-associated pregnancy. Therefore, SLE should still be considered a severe risk factor for pregnancy.

show abstract

Section: Introductionmentioning

confidence: 99%

Maternal and fetal complications associated with systemic lupus erythematosus

Hua

2020

Medicine

View full text Add to dashboard Cite

show abstract

“…National data from Colombia national health care register estimated a prevalence of 91.9/100,000 subjects, being more frequent in women (89% cases). When adjusted, female and male prevalence has a 7.9:1 female:male ratio [5]. The prognosis of SLE has vastly improved in recent years, and this is thanks to improved diagnostic and therapeutic methods.…”

Section: Introductionmentioning

confidence: 99%

Living with Systemic Lupus Erythematosus: A Profile of Young Female Patients

Macejová

Gecková

Husárová

et al. 2020

IJERPH

View full text Add to dashboard Cite

The aim is to describe a profile of systemic lupus erythematosus (SLE) patient (socio-demographic data, course of disease, health status, and health care utilization, SLE impact on their life, SLE awareness) and to explore the association of patient’s perspective with clinical indicators. Adult patients diagnosed by SLE were recruited in outpatient clinics (n = 76, 88% female, data collected in 2012–2016, Slovakia). The association of patients’ perspective (SLE status, health complaints during remission, SLE impact, hospitalizations) with clinical activity (European Consensus Lupus Activity Measurement Index—ECLAM) and inflammatory marker (erythrocyte sedimentation rate—ESR) was assessed by t-test for independent variables and one-way ANOVA. Almost 17.9% of patients reported relapse. During remission, they mostly suffered fatigue and pain. Nearly all patients were on chronic pharmacological treatment. Most of the patients assessed SLE impact on their life as restrictive (56.9%) or very restrictive (23.1%). The most frequent source of information was their physician, and 67.2% reported that they have sufficient information about the disease and its treatment. Only the association of SLE status and hospitalization with clinical activity (ECLAM) and inflammatory marker (ESR) were confirmed. With recent improvements in diagnostics and therapy options, the prognosis for patients with SLE has improved. Nevertheless, the impact of this disease on all areas of a patient’s life is extensive.

show abstract

“…We have described searching methods previously. [8][9][10][11] Due to recent updates on the database, the currently available information comprises only the period between 2015 and 2019. Briefly, we obtained the information for the whole country, for the period between January 1 st 2015 and December 31 th 2019.…”

Section: Palabras Clavementioning

confidence: 99%

Prevalence and Demographic Characteristics of Prostate Cancer Patients in Colombia: data from the National Health Registry from 2015 to 2019

Parra‐Medina

Barahona-Correa

Chaves

et al. 2021

Revista Urología Colombiana / Colombian Urology Journal

View full text Add to dashboard Cite

Background and Objective Prostate cancer is a multifactorial disease and is among the top five causes of death in men worldwide. The Colombian Ministry of Health has adopted the Integrated Information System on Social Protection (Sistema Integrado de Información de la Protección Social, SISPRO, by its Spanish acronym) registry to collect comprehensive information from the Colombian health system. The system provides close to universal coverage (around 95%). We aimed to establish the prevalence of prostate cancer in Colombia and to describe its demographics, based on data provided by SISPRO, openly available for scientific analysis. Methods Using the SISPRO data from 2015 through 2019, we analyzed the prevalence and demographic characteristics of patients diagnosed with prostate cancer. Results We identified a total of 43,862 patients with prostate cancer in the 5-year period and estimated a prevalence of 4.54 cases per 1,000 habitants, using as denominator males over 35 years old. We calculated a prevalence of early-onset prostate cancer (i.e., 35–54 years) of 0.14 per 1,000 habitants (791 cases in 5 years). The highest prevalence was observed in patients > 80 years (33.45 per 1,000 habitants). The departments with the highest prevalence were Bogotá, Valle del Cauca, Risaralda, and Boyacá, and the region with the lowest prevalence was Amazonas. Conclusion We describe the prevalence and demographics of prostate cancer in Colombia using the national healthcare system database. We observed that the prevalence has been increasing over time, and the distribution is variable according to regions, which may be related to racial or environmental causes, or access to the urologist. These factors should be addressed in further studies.

show abstract

Prevalence of systemic lupus erythematosus in Colombia: data from the national health registry 2012–2016

Cited by 44 publications

References 24 publications

Maternal and fetal complications associated with systemic lupus erythematosus

Maternal and fetal complications associated with systemic lupus erythematosus

Living with Systemic Lupus Erythematosus: A Profile of Young Female Patients

Prevalence and Demographic Characteristics of Prostate Cancer Patients in Colombia: data from the National Health Registry from 2015 to 2019

Contact Info

Product

Resources

About